Comparing NovoTTF-200T with Pembrolizumab for metastatic non-small cell lung cancer
Explore this study →
There are 2 groups in this study. Group A receives NovoTTF-200T and Pembrolizumab, together with one or more of: Platinum based chemotherapy. Group B, the comparison group, receives Pembrolizumab, together with one or more of: Platinum based chemotherapy.
Sites in Ottawa and Toronto
- Phase 3
- 2 groups
- Sites in Ottawa and Toronto
- Recruiting
Official title: LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non-small Cell Lung Cancer · NovoCure GmbH